Soluble trail as a marker of efficacy of allergen-specific immunotherapy in patients with allergic rhinoconjunctivitis

Medical Science Monitor

Volumn 18, Issue 10, 2012, Pages

  Yalcin, Arzu Didem ^a   Gumuslu, Saadet ^b   Parlak, Gizem Esra ^b   Bisgin, Atil ^c  

^a Division of Neonatology   (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Allergen specific immunotherapy; Allergic rhinitisskin prick test; Strail levels

Indexed keywords

ALLERGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; ARTICLE; BARLEY; BODY MASS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; GRASS; HAY FEVER; HUMAN; IMMUNOTHERAPY; MALE; MITE; OLIVE; PRICK TEST; PROTEIN BLOOD LEVEL; SMOKING; TREATMENT RESPONSE; WHEAT;

EID: 84867625376     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.883488     Document Type: Article

References (27)

1. Yalcin AD, Oncel S, Akcan A et al: Prevalance of allergic asthma, rhinitis and conjunctivitis in over 16 year old individuals in Antalya. Turkiye Klinikleri J Med Sci, 2010; 30(3): 888-94
2. Yalcin AD, Ozdemir L, Polat HH: Evaluation of socio-demographic characteristics of patients receiving spesific immunotherapy in Antalya. Respirology, 2011; 16(2): 191
3. Nicolaou N, Siddique N, Custovic A. Allergic disease in urban and rural populations: increasing prevalence with increasing urbanization. Allergy, 2005; 60(11): 1357-60
4. Tariq SM, Matthews SM, Hakim EA et al: The prevalence of and risk factors for atopy in early childhood: a whole population birth cohort study. J Allergy Clin Immunol, 1998; 101(5): 587-93
5. Rossi RE, Melioli G, Monasterolo G et al: Sensitization profiles in polysensitized patients from a restricted geographical area: further lessons from multiplexed component resolved diagnosis. Eur Ann Allergy Clin Immunol, 2011; 43(6): 171-75
6. Malone DC, Lawson KA, Smith DH et al: A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol, 1997; 99: 22-27
7. Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol, 2007; 35(4): 495-516
8. Opferman JT, Korsmeyer SJ: Apoptosis in the development and maintenance of the immune system. Nat Immunol, 2003; 4(5): 410-15
9. Chaudhari BR, Murphy RF, Agrawal DK: Following the TRAIL to apoptosis. Immunol Res, 2006; 35(3): 249-62
10. Tsokos GC, Tsokos M: The TRAIL to arthritis. J Clin Invest, 2003; 112(9): 1315-17
11. Lamhamedi-Cherradi SE, Zheng SJ, Maguschak KA et al: Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/mice. Nat Immunol, 2003; 4(3): 255-60
12. Berent-Maoz B, Salemi S, Mankuta D et al: TRAIL mediated signalingin human mast cells: the influence of IgE-dependent activation. Allergy, 2008; 63(3): 333-40
13. Yalcin AD, Gumuslu S, Parlak GE et al: Systemic Levels Of Ceruloplasmin Oxidase Activity In Allergic Asthma And Allergic Rhinitis. Immunopharmacol Immunotoxicol, 2012; [epub ahead of print]
14. Yalcin AD: The therapeutic efficacy and side effect of omalizumab. Respirology, 2011; 16(2): 192
15. Yalcin AD, Gorczynski RM,Parlak GE et al: Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: its relation to omalizumab treatment. Clin Lab, 2012; 58(1-2): 89-96
16. Yalcin AD, Bisgin A, Kargi A, Gorczynski RM: Serum soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to Omalizumab treatment. Med Sci Monit, 2012; 18(3): PI11-15
17. Robertson NM, Zangrilli JG, Steplewski A et al: Differential Expression of TRAIL and TRAIL Receptors in Allergic Asthmatics Following Segmental Antigen Challenge: Evidence for a Role of TRAIL in Eosinophil Survival. J Immunol, 2002; 169(10): 5986-96
18. Bisgin A, Kargi A, Yalcin AD et al: Increased sTRAIL levels were correlated with patient survival in BevacizumAb treated metastatic colon cancer patients. BMC Cancer, 2012; 12: 58
19. Bisgin A, Yalcin AD, Gorczynski RM: Circulating soluble tumor necrosis factor related apoptosis inducing-ligand (TRAIL) is decreased in type2 newly diagnosed, non-drug using diabetic patients. Diabetes Res Clin Pract, 2012; [epub ahead of print]
20. Kato M, Nozaki Y, Yoshimoto T et al: Different serum soluble Fas levels in patients with allergic rhinitis and bronchial asthma. Allergy, 1999; 54(12): 1299-302
21. Kargi A, Bisgin A,Yalcin AD et al: Increased serum sTRAIL level in newly diagnosed stage-IV lung adenocarcinoma but not squamous cell carcinoma, is correlated with age and smoking. XXI. World Congress of Asthma. 18-21 Agust 2012. Quebec, Canada Oral Presentation: 089. p: 37
22. Yalcin AD, Bisgin A: The Relation of sTRAIL Levels and Quality of Life In Omalizumab Using Severe Persistent Allergic Asthma Patients. Med Sci Monit, 2012; 18(8): LE9-10
23. Yalcin AD, Bisgin A, Gorczynski RM: IL-8, TGF-b and GCSF levels were increased in severe persistent allergic asthma patients with the anti-IgE treatment. XXI. World Congress of Asthma. 18-21 Agust 2012. Quebec,Canada Oral Presentation: 031 p: 22
24. Robbie-Ryan M, Brown M: The role of mast cells in allergy and autoimmunity. Curr Opin Immunol, 2002; 14: 728-33
25. Berent-Maoz B, Piliponsky AM, Daigle I et al: Human Mast Cells Undergo TRAIL-Induced Apoptosis. J Immunol, 2006; 176: 2272-78
26. Puxeddu I, Piliponsky AM, Bachelet I et al: Mast cells in allergy and beyond. Int J Biochem Cell Biol, 2003; 35: 1601-7
27. Robbie-Ryan M, Brown M: The role of mast cells in allergy and autoimmunity. Curr Opin Immunol, 2002; 14: 728-33